Quote · The Peter Attia Drive
#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.
Where this was said
How biomarkers changed Gayatri's perspective
At 1:47:25 · chapter starts 1:47:15
This short but emotionally resonant segment captures the intellectual journey at the heart of the episode. Gayatri Devi trained in an era when Alzheimer's was considered inexorably progressive — every patient declined, no exceptions. When she began seeing patients improve with treatment, her default assumption was misdiagnosis. It was only after spinal tap biomarkers became available in 2007, allowing antemortem confirmation of amyloid and tau pathology, that she had to confront a more unsettling possibility: these patients really did have Alzheimer's and they really were getting better [1] — Gayatri Devi "The next decade in Alzheimer's care will likely be defined by AI monitoring of subtle changes in cognitive patterns for early detection, ta…" 1:49:50 . Even then, it took her another five to eight years to truly internalize that belief. Now, after 32 years in the field, she holds it with conviction — a shift she describes as one of the most significant of her career.
For decades, Gayatri Devi assumed any Alzheimer's patient who improved had been misdiagnosed. Only when spinal tap biomarkers confirmed true Alzheimer's pathology in patients who then got better did she allow herself to believe improvement was real. It took five to eight more years before she truly believed it — and now she does.
Approximately 30% of patients enrolled in Alzheimer's drug trials did not actually have Alzheimer's by pathology, having been misdiagnosed clinically.
